The effectiveness of radioligand therapy is counterintuitive: as tumors shrink and PSMA binding sites decrease, less radiation is delivered to the cancer. The VISION trial showed the first two doses delivered more radiation to the tumor than the subsequent four, questioning the value of a fixed, prolonged treatment schedule.

Clinicians are concerned about the overuse of Stereotactic Body Radiation Therapy (SBRT) for oligoprogressive disease, a practice dubbed 'Pokemon' (gotta catch 'em all). This approach of sequentially radiating new lesions can delay the start of more effective systemic therapies and is not considered a standard of care.

Unlike traditional chemotherapy, radioligand therapy's toxicity may be inversely correlated with tumor volume. In low-burden disease, fewer cancer cells act as a 'sink' for the drug, potentially leading to higher radiation exposure and side effects in healthy, PSMA-expressing tissues like salivary glands.

Early in treatment, tumors are "target-rich" with high PSMA expression, creating an ideal window for radioligand therapy. Citing data from the VISION trial, new clinical trials are being designed to accelerate dosing and intensity upfront to maximize impact, then de-escalate as the target diminishes.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

Unlike traditional drugs, a radiopharmaceutical's safety is dictated by its physical location over time. The 'hot metal' analogy illustrates this: a drug that lingers in healthy tissue will cause damage. Therefore, designing drugs that rapidly target tumors and quickly clear from the body is paramount.

Radioligand therapy has a unique toxicity profile, described as 'the gift that keeps on giving,' where side effects can worsen even after the treatment course is complete. This contrasts with chemotherapy like docetaxel, where a patient's quality of life often rebounds and improves once the drug is stopped.

For patients with conventionally negative imaging but positive PSMA PET scans (oligometastatic disease), continuous intensified therapy may be overtreatment. A new paradigm involves metastasis-directed therapy followed by a short course of escalated treatment, then stopping to observe. This "time-limited" approach balances efficacy with reducing long-term treatment burden.

Unlike chemotherapy, radioligand therapy's effectiveness wanes as tumors shrink. With less PSMA target for the drug to bind to, less radiation is delivered to the cancer. This physical reality supports "adaptive dosing"—stopping treatment in high-responders to spare healthy tissue and resume later if needed.